Phase III Study With Venetoclax Combo Identifies New Biomarker for Relapsed/Refractory…

The phase III BELLINI trial demonstrated translocation (11;14) and high BCL2 gene expression are predictive of response to treatment with the addition of venetoclax to bortezomib plus dexamethasone in patients with relapsed/refractory multiple myeloma, according to the findings presented at the 2019 ASH Annual Meeting.

Read the full article here

Related Articles